Metabolic & Cardiometabolic
GLP-1 receptor agonists improves MASH / NASH (steatohepatitis)
In plain terms: Can GLP-1 drugs help fatty-liver disease (MASH/NASH), including the scarring?
Strong support Metabolic & Cardiometabolic
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 0.81
Yes for resolving the inflammation — robustly shown for semaglutide and tirzepatide; the harder fibrosis (scarring) benefit was null in early phase-2 but reached significance in the large phase-3 ESSENCE trial.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 0 contradict 0 tested null 2 mixed · 11 sources, 9 independent groups · 2 superseded — pooled inside a review, counted once
What the evidence shows
GLP-1 receptor agonists resolve the inflammatory component of MASH: across seven biopsy-confirmed randomised trials, semaglutide and the dual agonist tirzepatide improved histology, and network meta-analyses rank them first. Fibrosis is the harder endpoint and was not met in the earlier phase-2 work, so scarring improvement is less established than inflammation resolution.
The evidence (29)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Alzaki AA, Alqahtani MZ, Aman E, Asiri GM, Al Jibril MH, Desoky R, Alqahtani SA, Suhaqi L, Alkhalid SA, Alshareef DY, Desoky MS 2026 · Cureus | RCT | supports | high | Across seven biopsy-confirmed MASH RCTs, GLP-1 (semaglutide) and GIP/GLP-1 (tirzepatide) agonists improved histologic MASH resolution, with semaglutide achieving dual endpoints in phase 3 ESSENCE. |
| Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, Mehta PD, Brar AS, Sohal A, Goyal MK, Hatwal J, Batta A 2026 · World journal of diabetes | observational | supports | low | Narrative review of MASLD/T2DM: GLP-1 receptor agonists (among other antidiabetic agents) show hepatic benefits beyond glycemic control as part of emerging pharmacotherapy landscape. |
| Khalifa O, Arredouani A 2026 · Pharmaceuticals (Basel, Switzerland) | observational | supports | moderate | Comprehensive narrative review from GLP-1 discovery to FDA approval: extensive mechanistic, preclinical, and clinical evidence show GLP-1RAs reduce hepatic steatosis, attenuate inflammation, and impede disease progression, established as th |
| Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN 2016 · Lancet | RCT | supports | moderate | LEAN phase-2: liraglutide steatohepatitis resolution 39% vs 9% placebo with no fibrosis worsening; small (n=52). ↩ SUPERSEDED — pooled in the review above, counted once |
| Wang Y, Yi H, Sun W, Yu H, Tao W, Yu X, Jia D, Liu Y, Pandol SJ, Li L 2024 · Drugs | meta-analysis | supports | moderate | 24-wk NAFLD NMA: GLP-1RA improve hepatic steatosis/enzymes vs placebo; shorter horizon limits fibrosis read. |
| Tang M, Ma Y, Wang Y 2026 · Frontiers in endocrinology | meta-analysis | supports | high | Frequentist network meta-analysis of 34 studies/33 RCTs (Phase II/III, biopsy-proven MASH): GLP-1/GIP dual agonists had the highest MASH-resolution efficacy (RR 5.21) and GLP-1 RAs alone improved fibrosis (RR 1.51, 95% CI 1.09-2.10) versus |
| Malandris K, Charalampidis K, Loomba R, Sinakos E 2026 · Current diabetes reports | observational | supports | low | Narrative review: GLP-1 RAs and dual GIP/GLP-1 RAs demonstrate 'meaningful benefits' in steatohepatitis; semaglutide provides the most robust evidence for fibrosis benefit, with potential antifibrotic effects also for tirzepatide. |
| McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB, SOUL Study Group 2025 · N Engl J Med | RCT | supports | low | SOUL tested once-daily oral semaglutide against placebo in 9,650 people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both, over a median 49.5 months. Its reported outcomes are cardiovascular and renal: major adverse cardiovascular events fell from 13.8% to 12.0% (hazard ratio 0.86, 95% CI 0.77 to 0.96), while the kidney composite did not differ significantly. No liver endpoint is reported, so the trial says nothing about steatohepatitis. |
| Newsome PN, Sejling AS, Sanyal AJ 2021 · N Engl J Med | RCT | mixed | moderate | Authors' reply reaffirming phase-2 result: strong NASH resolution, fibrosis endpoint not met — honest limitation. |
| Weng J, Huang A, Berake TB, Chen SL, Yan BM, Karagozian R 2026 · Gastroenterology research | observational | supports | low | Retrospective cohort (n=229 MASLD patients on GLP-1 RAs, 29 with baseline FIB-4≥1.3): mean FIB-4 decreased from 1.94 to 1.73 over 12 months (95% CI -0.38 to -0.05, P=0.019), with significant AST/ALT/BMI/A1c reductions; FIB-4 improvement ind |
| Lin RT, Sun QM, Xin X, Ng CH, Valenti L, Hu YY, Zheng MH, Feng Q 2024 · Metabolism | meta-analysis | mixed | high | NMA of MASLD drugs: GLP-1RA and polyagonists improve histology/resolution; THR-beta/FGF21 stronger for fibrosis specifically. |
| Newsome 2025 · N Engl J Med | RCT | supports | high | ESSENCE phase-3 (240wk): semaglutide 2.4mg — steatohepatitis resolution 62.9% vs 34.3% AND fibrosis improvement 36.8% vs 22.4% (both P<0.001). |
| Mahoon D, Kellany F, Khan I, Khan S, Butler AE 2026 · International journal of molecular sciences | RCT | supports | moderate | Systematic review (PROSPERO CRD420261337353) of 12 studies: GLP-1RAs (semaglutide, liraglutide, dulaglutide, beinaglutide) most consistently reduced hepatic fat, with strongest histological benefit for steatohepatitis resolution in non-cirr |
| Tsakiridis EE, Steinberg GR 2026 · Diabetes, obesity & metabolism | observational | supports | moderate | Mechanistic review: GLP-1-based therapies consistently improve steatosis and steatohepatitis via reduced hepatic nutrient flux, improved adipose insulin sensitivity, and weight-independent anti-inflammatory effects, despite limited direct h |
| Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ, SYNERGY-NASH Investigators 2024 · N Engl J Med | RCT | supports | high | SYNERGY-NASH: tirzepatide MASH resolution 44-62% vs 10% placebo (dose-dependent, P<0.001); fibrosis signals favorable. ↩ SUPERSEDED — pooled in the review above, counted once |
| Dos Santos Borges R, Abreu ES, Berton GG, de Paula LH, Conegundes AF, Martins JMB, Martins MAB, Dahbour AS, Fernandes MV, Abdelmalek MF 2026 · JHEP Rep | meta-analysis | supports | high | SR/MA of GLP-1RA in MASH w/ fibrosis: consistent steatohepatitis resolution; pooled fibrosis benefit now emerging. |
| Abenavoli L, Loricchio AG, Lopez I, Morano D, Ismaiel A, Dumitrascu DL, Luzza F 2026 · Medicina (Kaunas, Lithuania) | observational | supports | low | Narrative review: GLP-1 receptor agonists reduce hepatic steatosis, inflammation, and fibrosis-related biomarkers, primarily via weight loss and improved insulin sensitivity; dual GLP-1/GIP agonists (tirzepatide) show superior outcomes; fib |
| Damen JAA, Idema DL, Vernooij RWM, Huis In 't Veld LF, Kusters MPT, Lokerse ME, de Kanter E, Spijker R, van der Braak K, Jenniskens K, Oerbekke MS, Hooft L 2026 · Ann Intern Med | meta-analysis | supports | low | The prior extract ('improves obesity-linked steatotic liver disease markers') has NO basis in this paper - the strings liver, hepat, steato, MASH and NASH return zero hits across the whole record. The review's stated scope is 'pharmacologic treatments for weight management in overweight or obesity in adults' for 'outcomes such as mortality, weight loss, and quality of life', and its results sentence is 'Semaglutide probably reduced mortality and major adverse cardiovascular events (MACE), and both semaglutide and tirzepatide led to the greatest weight loss compared with placebo and/or LI in pairwise and network meta-analyses.' OFF-SCOPE: wrong outcome. Quality dropped to low as this source carries no information on the claim at all. Read from abstract only (2026-08-19). |
| Tornea DA, Goldis C, Isaic A, Motofelea AC, Sima AC, Ciocarlie T, Crintea A, Diaconescu RG, Motofelea N, Goldis A 2026 · Pharmaceutics | meta-analysis | supports | high | Systematic review and meta-analysis of 20 RCTs: GLP-1 agonists significantly increased MASH resolution without fibrosis worsening (RR 3.03, p<0.0001) and fibrosis improvement by ≥1 stage (RR 1.45, p<0.00001) overall, but in patients without |
| Pantea I, Repanovici A 2026 · Journal of diabetes research | observational | supports | moderate | Bibliometric + evidence review of tirzepatide: SYNERGY-NASH trial showed high rates of MASH resolution without fibrosis worsening and 'meaningful fibrosis regression' at 52 weeks; EASL-EASD-EASO guidelines recommend tirzepatide for MASLD wi |
| Amorim Moreira Alves G, Teranishi M, Majumdar R, Khan F, Dodeja M, Teixeira de Castro Goncalves Ortega AC, Acerboni M, Perera Molligoda Arachchige AS, James F 2026 · Chronic Dis Transl Med | observational | supports | moderate | Narrative review restating biopsy-based trial results: liraglutide (LEAN, 48 weeks) resolved steatohepatitis without worsening fibrosis in about 39% versus 9% on placebo; semaglutide phase 2 (72 weeks) in 59% at 0.4 mg versus 17%, with fibrosis improvement 43% versus 33%, not significant; semaglutide 2.4 mg phase 3 at 72-week interim in 62.9% versus 34.3%, fibrosis improvement 36.8% versus 22.4%; tirzepatide (SYNERGY-NASH) 44-62% versus 10%. In compensated cirrhosis there was no fibrosis improvement, 11% versus 29%, and no difference in resolution. |
| Dinkov B, Pendicheva-Duhlenska D 2026 · Biomedicines | observational | supports | moderate | Narrative review (33 studies): tirzepatide achieved MASH resolution in 44-62% of patients in phase 2 SYNERGY-NASH; semaglutide FDA-approved for MASH with fibrosis based on Phase 3 ESSENCE trial; preclinical data show gut-microbiome-mediated |
| Zacharia GS, Gongati SR, Kharel A, Jacob A 2025 · Cureus | observational | supports | moderate | Narrative review: semaglutide therapy is associated with resolution of steatohepatitis and improvement in hepatic fibrosis; approved (with resmetirom) for non-cirrhotic MASH with moderate-to-advanced fibrosis. |
| Choi S, Jung JS, Seo YS, Song S, Ham J, Chung H, Ramadan Y, Choi K 2026 · Journal of cellular and molecular medicine | observational | supports | low | Mechanistic review proposing an AMPK-centric framework for MASH therapeutics: GLP-1 receptor agonists (e.g., semaglutide) are framed as acting predominantly through systemic effects (weight loss, glycemic control) converging on AMPK activat |
| Mahalingam S, Kharbanda KK, Casey CA, Rasineni K 2026 · Frontiers in pharmacology | observational | supports | low | Narrative review: GLP-1 RAs' efficacy in resolving MASH is 'increasingly well documented,' via weight loss, improved insulin sensitivity, reduced hepatic lipogenesis, and anti-inflammatory/AMPK-mediated effects; extension to ALD/MetALD and |
| Wang MJ, Jiang YN, Li PP, Wu YJ 2026 · Diabetes, metabolic syndrome and obesity : targets and therapy | meta-analysis | supports | high | PRISMA systematic review + meta-analysis of 25 RCTs (n=2481): GLP-1 RAs significantly increased MASH resolution without fibrosis worsening (OR 4.04, 95% CI 2.69-6.05, high GRADE certainty) but showed no significant fibrosis improvement (OR |
| Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA, NN9931-4296 Investigators 2021 · N Engl J Med | RCT | supports | high | Phase-2, 72-week, double-blind, placebo-controlled, biopsy-confirmed NASH (n=320; NCT02970942, Novo Nordisk). Primary endpoint, the claim's own outcome: 'The percentage of patients in whom NASH resolution was achieved with no worsening of fibrosis was 40% in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (P<0.001 for semaglutide 0.4 mg vs. placebo).' The trial's fibrosis-stage null (43% vs 33%, P=0.48) is a DIFFERENT outcome from this claim's steatohepatitis object and is logged as a candidate for a fibrosis claim, not folded in here. Limits: only the top of three doses was formally significant, dose-response non-monotonic, endpoint analysis restricted to the 230 F2/F3 patients. |
| Villaseñor-Tapia EC, Franco-Acevedo A, Rosas-Campos R, Armendariz-Borunda J 2026 · Pharmaceutics | observational | supports | low | Narrative review: GLP-1 receptor agonists show 'clinically meaningful improvements' in metabolic parameters and hepatic steatosis, though impact on fibrosis and long-term disease modification remains uncertain. |
| Cruz AM, Lima BCV, de Ferreira JESM, Teles RB 2026 · European journal of clinical pharmacology | RCT | supports | high | Systematic review of clinical studies: semaglutide phase 3 achieved MASH resolution w/o fibrosis worsening in 62.9% vs 34.3% placebo (p<0.001); phase 2 NASH resolution 59% vs 17% (p<0.001) but no significant fibrosis improvement (43% vs 33% |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.